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Abstract Since its discovery in 1988, B-type natriuretic
peptide (BNP) has been recognized as a powerful cardiovas-
cular biomarker for a number of disease states, specifically
heart failure. Concurrent with such a discovery, much effort
has been allocated to the precise monitoring of physiological
BNP levels. Thus, it can be used to guide the therapy of heart
failure and determine the patient’s stage of disease. Thus, we
discuss in this article BNP as a potent biomarker. Subse-
quently, we will review the progress of biosensing devices as
they could be applied to monitor BNP levels as assays,
benchtop biosensors and implantable biosensors. The ana-
lytical characteristics of commercially available BNP assays
are presented. Still emerging as a field, we define four obsta-
cles that present opportunity for the future development of
implantable biosensor: foreign body response, sensor
renewability, sensitivity and selectivity.
Keywords Brain natriuretic peptide  Biomarker  Heart
failure  Implantable biosensor
Introduction
A recent report from the American Heart Association
estimated that 85.6 million Americans over the age of 20
have one or more types of cardiovascular disease (CVD).
Of these, 5.7 million are estimated to have heart failure
(HF). One in nine deaths has HF mentioned on the death
certificate. This was expected to cost billions of US dollars
in medical services, medications and lost productivity; HF
represents a significant drain on health resources both in
the US and in many other nations. Projections show that by
2030, the prevalence and the total cost of HF will increase
46 and 127 %, respectively [1].
While an early diagnosis may help control the condition
and prevent rapid decline, it would obviously be preferred
to identify those patients at high risk of HF and offer
preemptive specific and aggressive treatment before its
onset. Thus, began the search for a window into HF and a
metric to quantify the condition.
Why biomarkers?
Biomarkers are biological analytes detectable in the blood
stream under specific physiological conditions [2]. As such,
biomarkers are a cost-effective, precise way of peering
through a patient’s physiological window and differenti-
ating disease states in complex patients [3]. In particular,
cardiovascular biomarkers promise to offer such a window
into HF. Though controversy exists regarding the existence
of an ideal cardiovascular biomarker to be considered
useful in monitoring HF [2], an ultimate biomarker would
be highly sensitive and specific for HF, be released quickly
for early diagnosis, be persistent for a reasonable amount of
time to allow for a diagnostic window and be quantified
accurately and economically in a manner that would reflect
changes in both the patient’s clinical status and prognosis
[4, 5]. The biomarker may be a by-product of the disease
state and may also directly participate in its pathogenesis or
modulation [6]. Among cardiovascular biomarkers, brain
natriuretic peptide and N-terminal pro-B-type natriuretic
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peptide (NT-pro-BNP) have emerged as powerful diag-
nostic tools for acute HF and as screening tools for
detecting left ventricular systolic and diastolic dysfunction
[7–10]. Several clinical trials have also evaluated the
benefit of monitoring BNP and NT-pro-BNP concentra-
tions to guide the therapy and the management of chronic
heart failure [11–13]. Some studies reported encouraging
trends [14–17], and others showed benefits in subgroups of
participants [18–20], while other trials showed no advan-
tages of peptide-guided compared to clinically guided
therapy [21–25]. On the other hand, a recent meta-analysis,
conducted by Savarese et al. [26] on 2686 patients from the
previously stated 12 trials, showed that natriuretic peptide-
guided therapy is associated with outcome benefits.
Scope of this review
This review aims to survey the fields of BNP research and
analyte detection techniques, specifically implantable BNP
biosensors. Volumes have been dedicated both to the elu-
cidation of BNP and biosensor technology. In this review,
detail will be provided for the purpose of allowing the
reader to grasp the skeleton concepts, thereby providing a
foundational appreciation for BNP as a biomarker as well
as for the necessity of an effective instrument to measure
BNP. Our hope is to accomplish this by providing an
overview of current and past BNP research without
becoming encumbered by minutia. Should the reader like
to engage the overwhelming amount of the BNP literature,
we have attempted to provide ample references that will
serve as a springboard for further research.
The field of biosensors is vast and constantly progress-
ing; a complete account is beyond the scope of this review.
After a brief introduction of assays and what we will
consider benchtop biosensors, our gaze will fall more
specifically upon implantable biosensors. While examples
of implantable biosensors will be mentioned to provide
something of a disciplinary context and to provide an
appreciation of the challenges experienced in
implantable biosensor development, we will focus discus-
sion on those challenges and potential for growth as it
relates more specifically to BNP implantable biosensors.
BNP
Discovery and structure of BNP
Originally named porcine brain natriuretic peptide (pBNP)
after the porcine brain from which it was first derived,
pBNP is a 26 amino acid chain that shares considerable
sequence similarity with alpha human atrial natriuretic
peptide (a-hANP) [27]. Another form with an additional
six residues at the N-terminus, BNP1-32 [28] and a larger
precursor form, 12 kDa, have been found, respectively, in
the pig brain and heart [29]. It soon became clear that the
main source of this natriuretic peptide was the heart rather
than the brain [30, 31].
Stimulus, production and processing
BNP is produced predominantly in the left ventricular
myocardium in response to myocyte distension caused by
ventricular volume expansion or pressure overload [32–
35]. Though somewhat unclear, it seems that BNP is reg-
ulated by post-translational processing; therefore, its gene
product can increase very rapidly in response to stimulus
[33, 36]. This is significant because ANP, which shares a
similar stimulus, is regulated at the level of release from
storage granules and therefore does not increase as rapidly
or in as great a magnitude [33, 36, 37].
When threshold is reached, BNP is produced as a 134
amino acid pre-pro-BNP peptide that is cleaved soon after
secretion to yield the 108 amino acid pro-BNP. Further
cleavage produces the biologically active 32 amino acid
BNP peptide (BNP1-32) which contains a 17 amino acid
ring closed by a disulfide bond and also the linear 76 amino
acid N-terminal peptide (NT-pro-BNP1-76) [33]. The bio-
logically active BNP1-32, the pro-BNP and the NT-pro-
BNP1-76 all can be measured in the plasma, as will be
described below [36, 37].
Mechanism of action
Natriuretic peptides bind to three kinds of membrane bound
natriuretic peptide receptors (NPR): NPR-A, NPR-B and
NPR-C. These receptors and their respective activations are
described in some detail by Vanderheyden et al. [36] and
will not be delineated here. However, it is important to note
that BNP1-32 mediates its biological actions by binding to
NPR-A, which is abundant in the vascular endothelium
system and is also present in the brain, the kidney and the
adrenal glands [38–40]. BNP has been shown to be a
counter-regulatory molecule for the renin–angiotensin–al-
dosterone system, to improve glomerular filtration rate and
filtration fraction and to have diuretic, natriuretic and
vasodilatory effects [41]. Thus, BNP dilates blood vessels,
lowering vascular resistance while facilitating higher stroke
volume, and also causes increased sodium secretion from
the kidneys, increasing urine production while decreasing
blood volume and therefore blood pressure.
Degradation and elimination
The degradation and elimination mechanisms of BNP are
only partly understood and are somewhat surrounded by
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controversy [42–45]. Of course, these must be further
researched whether BNP is to be used as a predictable and
precise biomarker of physiological condition; if it is to be a
window into an internal physiology, we must know how
long the window opens, why it opens, what causes the
window to close and how clearly we can see through.
Information will be presented here to give an appreciation
of the complexity of tracking the moving target that is
BNP. At present, research has demonstrated that the
combined clearance of BNP by NPR-C, the cleavage and
inactivation by neutral endopeptidase (NEP) and the
clearance by normal glomerular filtration contribute to an
estimated half-life of 20 min compared to 90–120 min for
NT-pro-BNP which is only eliminated by renal filtration
[36, 44, 46–48]. In addition to the NEP, BNP is also
cleared through proteolysis by other peptidases including
serine proteases, peptidyl arginine aldehyde proteases and
kallikrein-like proteases [48].
A complication to measuring BNP concentrations (or
any degradable biomarker, for that matter) is its sensitivity
to degradation. Proteolytic cleavage of BNP’s highly sen-
sitive N-terminal residues may begin within circulation or
immediately after blood collection making precise mea-
surements of physiological levels difficult to achieve.
Chromatographic fractionation and analysis of plasma
from heart failure patients collected in siliconized tubes to
avoid contact activation of kallikreins have suggested that
prior to any in vitro activation of proteases, there is a
natural in situ activity that results in in vivo cleavage of the
two amino acids at the N-terminus (Ser-Pro) [49]. The
dipeptidyl peptidase IV, a serine protease that cleaves the
N-terminal dipeptide after a proline amino acid, was
proved to be responsible of this cleavage [42].
C-terminal proteolysis can occur in vivo and/or in vitro
by activation of the kallikrein contact-activated system
[50]. It has been reported that both the disulfide bond-
mediated ring and the carboxyl terminal structure are
stable in blood samples unless blood coagulation factors
are activated, which often occurs when blood comes into
contact with foreign surfaces, such as a glass test tube [51].
This type of degradation can be inhibited by using EDTA
and siliconized glass tubes for biofluid collection and by
the addition of kallikrein and serine protease inhibitors [49,
52–54].
Despite the important physiological role played by BNP
as a natural hormone and its importance as a diagnostic
analyte, little is known of the structure of circulating BNP
and of its immunoreactivity, both of which are essential for
its quantification. Various groups have found that BNP
exists in plasma as two major forms: low molecular weight
and high molecular weight corresponding to BNP1-32
(*3–4 kDa) and to pro-BNP1-108 (*30–40 kDa), respec-
tively. Reversed-phase HPLC of extract from low
molecular weight fraction of gel-filtration HPLC has shown
that BNP1-32 is formed during blood circulation and con-
sists of digested pro-BNP1-108. Little immunoreactivity was
observed for the BNP fragments: BNP1-32, BNP3-32, BNP4-
32 and BNP10-32 [45]. The high molecular weight which is
about three or four times as large as that of pro-BNP
(*12 kDa) and was reported by some authors to be the
oligomerization product of pro-BNP which tend to form
trimers or tetramers due to a leucine zipper motif in the
pro-region [49, 53, 54]. Schellenberger et al. [55] have
demonstrated that BNP precursor is an O-linked glyco-
protein and that the high molecular weight is likely due to
the glycosylation [55, 56]. It has been published also that
pro-BNP is the predominant form displaying BNP
immunoreactivity in patients with heart failure [56, 57].
As a marker for heart failure
BNP has emerged as a powerful sensitive and specific
diagnostic and prognostic tool for the onset of acute heart
failure and as a screening tool for detecting left ventricular
systolic and diastolic function [8]. HF is characterized by a
decrease in stroke volume, leading to insufficient cardiac
output to meet the body’s needs. Concomitant with this
decrease in stroke volume is an increase in right atrial
pressure or filling pressure. This high filling pressure
stretches the walls of the heart, causing BNP release as a
kind of biological call for help, as described above,
decreasing blood volume and therefore blood pressure.
Though BNP may not be an appropriate biomarker for all
cardiovascular conditions, it has been sufficiently demon-
strated to be specific for numerous disease states.
BNP can serve as a biological marker in more than the
stereotypical adult patient with HF. Recent studies have
demonstrated that BNP is significantly higher in neonates
with congenital heart disorders, such as hemodynamically
significant left to right shunts [2, 58]. Pregnant women with
severe preeclampsia, the most common pregnancy disorder
resulting in significant maternal and neonatal morbidity
and mortality, have also been observed to have elevated
BNP level [2].
As a diagnostic tool, BNP can help narrow down a
differential diagnosis; i.e., it can be used to differentiate
dyspnea due to HF (high BNP levels) from dyspnea due to
other causes (normal BNP levels) [59, 60]. Early diagnosis
is critical, specifically in the elderly population, where
misdiagnosis of HF can easily and rapidly lead to mor-
bidity and mortality [61]. BNP levels also predict sudden
cardiac death and ventricular arrhythmias [60].
Because BNP can also be used to measure the severity
or progress of HF, it can also be used to monitor treatment
efficacy in acute HF patients, wherein levels would be
expected to decrease, albeit not original values [61–63].
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Current studies are underway to further test the efficacy of
HF treatment guided by BNP levels [7]. Currently, BNP is
advocated as an important indicator in determining hospital
discharge and future prognosis [64]. Regarding the most
efficacious monitoring frequency, Dhaliwal et al. [61]
observed that multiple BNP measurements did not provide
a prognostic advantage over a single measurement when
considering ‘‘disease effect’’ or ‘‘disease modifiability.’’
However, as noted, these data were gathered from a rela-
tively small population size (n = 203) given treatment
independent of information gleaned from BNP levels,
leaving the possibility that continuous monitoring still
promises to provide additional indicators for treatment
decisions [61].
BNP monitoring
With the emergence of BNP as a useful biomarker, sev-
eral techniques have been applied to assess its concen-
tration in blood. What follows is a brief summary of
assays, benchtop biosensors and implantable biosensors
concluding with four areas we have identified as potential
space for growth.
Assays
The first assays for BNP were competitive immunoassay
methods using radio-labeled tracers (RIAs: radio
immunoassays) [61, 65]. However, these assays suffered
from large differences in specificity due to the presence of
several related peptides in plasma or tissues samples, which
could interfere with a competitive immunoassay. To
overcome these problems, a non-competitive immunora-
diometric assay (IRMA) method based on a two-site
sandwich immunometric measurement was proposed and
has demonstrated increased specificity for BNP [66–68].
More recently, micromosaic immunoassays (lMIAs) have
been developed to simultaneously screen for the presence
of multiple cardiac biomarkers including myoglobin, car-
diac Troponin I and C-reactive peptide. The lMIA repre-
sents both a step in the evolution in the immunosensor and
a widespread sentiment for the necessity of monitoring
cardiac biomarkers [69].
Though quickly acknowledged as a useful tool in
monitoring HF, it took 12 years from its discovery until the
first BNP assay received clearance from the Food and Drug
Administration (FDA) in 2000. Table 1 shows the analyt-
ical characteristics of commercial BNP assays as stated by
their respective manufacturers [70]. However, several
studies demonstrate that there are marked differences in
analytical performance and measured values among these
commercial methods [44, 71–73].
Of particular note is that commercially available BNP
assays are heterogeneous and measure both pro-BNP and
the breakdown products of BNP1-32 [73–75]. BNP1-32
varies according to disease progression being diagnosti-
cally significant, but thus far, we do not have the tools to
accurately differentiate the molecular forms. So far,
researchers are not capable of differentiating the molecular
forms of these peptides, such as different cleavage points
and post-translational modifications, which may vary
depending on the pathophysiological state of chronic HF
[72, 73, 76].
Though by and large assays have been effective in their
specific realms, hours often pass from when a test is
ordered until the results are ready. New developments have
led to the production of point-of-care (POC) assays that
allow for more rapid testing. Unfortunately, POC assays
sacrifice reliability in pursuit of practicability as noted by
[5, 77]. Variations in chip-based immunoassays such as
that developed by Wang et al. [78] allow for faster assay
time (15 min) and multiple marker quantification, but they
still require trained technicians who, in order to provide
necessary monitoring, must repeatedly withdraw blood
samples for analysis, another drawback of many assay
techniques [5]. In addition to these mechanical disadvan-
tages, because of the temporal limitations of assays, mon-
itoring BNP via assay is like trying to watch a film three or
four frame per hour: You cannot see the continual motion
of BNP levels. Therefore, in addition to being painful and
time-consuming, assays suffer from the inability of cap-
turing real-time information that reflects an individual’s
cycle, direction and trends throughout the day [78, 79].
Benchtop biosensors
Notwithstanding the availability of the above assays,
biosensors continue to be developed. As stated, biosensors
are electrical, optical, chemical or mechanical devices with
the capability to detect biological species selectively [80,
81]. Put another way, a biosensor is simply an electronic
device that produces electronic signals as the result of
biological interactions [80]. Like assays, to be reliable,
biosensors must possess a high level of sensitivity and
selectivity for a desired molecule and are therefore usually
designed to target one species. In addition, to be clinically
useful, a biosensor must give rapid feedback. The eco-
nomics of biosensors are such that defining a balance
between the competing qualities of sensitivity, selectivity
and response time is often hard to strike and becomes
somewhat of an engineering tug-of-war as one must often
take precedent at the expense of the other; for example,
increasing selectivity with the addition of a zwitterionic
semipermeable nanomembrane might also degrade
response time [82]. Each biosensor, therefore, is developed
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with specific application in mind and therefore a specific
equilibrium between sensitivity, selectivity and response
time. More will be said of sensitivity and selectivity in
section ‘‘Opportunities for future development’’ below.
There are many biosensor concepts. To use the classi-
fication set forth, they are generally divided into two
groups: catalytic sensors and affinity sensors. Catalytic
sensors employ enzymes, microorganisms or whole cells to
catalyze biological interactions with a target substance.
When this target substance is altered, it creates a change in
the electrical properties of the device, thereby generating a
response signal. Affinity systems use antibodies, receptors,
nucleic acids or other members of a binding pair to form
specific molecular interactions. When these reactions
occur, there is a change in the molecular dipoles of the
binding pair, which can be sensed by the device and
therefore serve as a response signal.
Most similar to immunoassays are electrochemical
enzyme immunoassays [82–84] and on-chip enzyme
immunoassays such as the microfluidic device with a
portable surface plasmon resonance (SPR)-based sensor
reported by Kurita et al. [85]. This SPR-based sensor
indirectly measure BNP by quantifying the activity of
acetylcholine esterase attached to an anti-BNP antibody.
Teramura et al. [86] have developed an SPR biosensor on a
sandwich-type immunoassay using two kinds of mono-
clonal antibodies. A clever application of streptavidin-
conjugated nanobeads reported by Mischak et al. [87]
Table 1 Analytical characteristics of commercial BNP assays as per the manufacturer (70)
Commercial
diagnostic tests






NH2 terminus and part of the ring
structure (Scios), murine
monoclonal AB, aa 5–13




Assist in diagnosis of HF
Assess severity of disease
Alerea
Triage BNP
NH2 terminus and part of the ring
structure (Scios), murine
monoclonal AB, aa 5–13
BNP (Biosite), murine omniclonal
AB, epitope not characterized
Recombinant
BNP










BNP (Biosite), murine omniclonal
AB, epitope not characterized
NH2 terminus and part of the ring
structure (Scios), murine















(Shionogi), murine monoclonal AB
Synthetic
BNP










Ring structure (KY-hBNPII) murine
monoclonal AB, aa 14–21
COOH terminus (BC-203), murine
monoclonal AB, aa 27–32
Synthetic
BNP 32




likelihood of future HF
in ACS patients
Pending FDA clearance
Shionogi COOH terminus (BC-203), murine
monoclonal AB, aa 27–32








COOH terminus (BC-203), murine
monoclonal AB, aa 27–32





CHF congestive heart failure, ACS acute coronary syndrome, aa amino acid, AB antibody
a Both the Alere and Beckman systems use the same two antibodies, but due to their different assay formats, designation of the monoclonal and
omniclonal antibodies as capture and detection antibody is not absolute
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allows an SPR sensor to detect changes at the level of
picogram (pg/ml), a concept with many potential applica-
tions to biosensors. Other concepts for detecting cardiac
biomarkers have also been developed such as nanofluidic
channel-based and nanoparticle-enhanced florescence-
based sensors [86], a silicon nanosensor for diagnosis of
cardiovascular proteomic markers [88] and a polyaniline
nanowire-based conductometric biosensor [89].
Though clinically useful, in vitro biosensors suffer from
many of the same disadvantages as assays. Because they
are extra-dermal, body fluids must either be withdrawn for
analysis or a probe must be temporarily inserted into tissue
to measure internal conditions; both are time-consuming,
inconvenient and painful. In addition, the scope of most
biosensors is limited to in vitro analysis either because they
are too large to be effectively implanted or because they
contain toxic materials and therefore cannot be used
in vivo, a complication that will become significant as we
discuss implantable biosensors below.
Implantable biosensors
To facilitate discussion, we will group implantable biosen-
sors into two functional categories based on location: sub-
cutaneous and vascular. As a class, implantable biosensors
offer many advantages over external biosensors and assays,
the greatest being valuable, real-time information. Real-time
information allows more rapid modification of treatment to
suit dynamic physiological conditions as well as earlier
detection of threatening disease states [90]. As noted by
Hirsch et al. [91], because traditional analyte monitors
provide only a snapshot of physiological conditions with no
indication to trend or rate of change, adjusting treatment and
predicting disease states on this basis involves considerable
guesswork, especially when self-administered as in the case
of diabetes. Real-time monitoring permits moment-by-mo-
ment understanding of an individual’s biological rhythms
throughout the day and how an individual responds to such
things as exercise, meals, pregnancy or other events [7, 91].
Additional benefits of the implantable biosensor over
assays or benchtop biosensors include the avoidance of
much of the inconvenience, pain and time demands of
drawing blood for periodic, quotidian or post-prandial
analysis. There are, of course, psychological as well as
economic advantages and should not be underestimated. In
determining the causes of low adherence to monitoring
schedules, recent evidence has pointed not to lack of
patient education, as was previously thought, but to the
consistent psychological and economic burden found with
in vitro analysis [92, 93].
Because of their obvious application to diabetes man-
agement, much effort has been made to develop continuous
glucose monitoring system (CGMS) [94–97]. Due to the
molecular nature of glucose, the actual monitoring mech-
anisms of glucose, chemosensors, are technically different
from the catalytic or affinity sensors used to quantify levels
of proteins like BNP. The implantable glucose biosensors
described below, therefore, serve to demonstrate not proof
of technology, but proof of concept and of overall design.
Subcutaneous implantable biosensors
Subcutaneous biosensors are often needle-shaped and
transdermal with the actual sensor implanted in the sub-
cutaneous tissue and a lead wire extending to an extra-
dermal monitoring display. Many implantable glucose
sensors have been developed [91, 95, 97–99]. The first
commercially glucose monitoring systems were initially
labeled for up to 3 days of wear [100]. Next, the wear time
was extended to 7 days [101]. Many sensors are coupled to
insulin pumps that automatically regulate glucose levels
within proscribed levels, alerting the patient when a
threshold is breached [102, 103].
While subcutaneous sensors provide the benefits of real-
time monitoring and do not require body fluids to be drawn
for analysis, because they are part external, they possess
disadvantages of decreased free movement, poor esthetic
appeal and risk of infection [91, 104]. Extensive ongoing
research is aiming to increase the sensor lifespan [105–
109]. So far, patient trials have returned favorable results
[110–112].
Vascular implantable biosensors
As suggested by the name, vascular implantable biosensors
are inserted into a vessel and can either be catheter based or
non-catheter based. Because of their suitability to cardio-
vascular applications, the majority of vascular
implantable biosensors have been developed to be specific
for cardiovascular biomarkers such as BNP.
Catheter-based systems can be deployed on an intrac-
ardiac lead or other delivery device as a stand-alone system
or they can be incorporated onto an implantable medical
device such as a pacemaker, defibrillator or cardiac
resynchronization system [91]. Non-catheter-based sensors
are often incorporated onto stents and are among the more
advanced of this class [82]. Both are contained completely
within the body (i.e., without any external anchors, leads or
probes) and transmit transdermal signal to an external
monitoring device via a telemetry device that utilizes radio
waves [113, 114].
Because they are completely internal, implan
table biosensors sidestep complications such as decreased
free movement and infection which are common to trans-
dermal catheters and needle-like probes [104, 115]. Non-
catheter-based sensors have the added advantage of being
572 Heart Fail Rev (2016) 21:567–578
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localized to a specific intravascular region, thereby
decreasing risk of damage to arterial walls.
As the next step in the biosensor evolution, vascular
biosensors are still very much in the developmental pro-
cess. While internalization is the implantable biosensor’s
greatest asset, it is also its greatest obstacle as two com-
plications quickly arise: evasion of the foreign body
response and renewability; both are necessary to insure the
longevity of the device. Therefore, in addition to the
technical hurdles of selectivity, sensitivity and respon-
siveness present in other sensors, in vivo applications must
also hurdle sustainability within a hostile host environment
and continuity of function [110].
Opportunities for future development
Foreign body response
One problem specifically pertinent to vascular
implantable biosensors and yet to be overcome is the
matter of the foreign body response, or biofouling. As
defined, biofouling is the accumulation of proteins, cells
and other biological materials on a surface. This accumu-
lation causes loss in sensitivity and/or activates the immune
response that encapsulates the sensor in fibrous scar tissue
as part of the body’s normal healing process. Biofouling
arises with any implantable device and therefore has been
investigated by many scientists with some success [116,
117].
Gant et al. [118] have developed a coating that expands
and contracts with variances in temperature, thus in essence
sloughing off any buildup of cells while changing the
surface hydrophobicity of the implant to deter further
buildup. Though conceptually appealing, complexities
arise when considering how to affect and control such a
temperature change in vivo. Furthermore, due to the tem-
perature sensitive nature of the hydrogel membrane, it is
unclear what effect the bodies’ natural temperature
rhythms (daily, menstrual, etc.) would have on the efficacy
of the material which demands calibration within a specific
temperature range.
Other attempted solutions to the foreign body response
have been addition of an external silicon membrane,
composite layers of carbon nanotubules and other nano-
porous membranes [118], zwitterionic coatings [119],
thermoresponsive double network nanocomposite (DNNC)
membrane [120] and matrices of proteases designed to
degrade proteins bound to biosensor surfaces [121].
Though preliminary studies on glucose sensors have been
hopeful, because the exact mechanism of biofouling is still
under investigation, attempts to prevent or deter the process
are speculative at best [81].
Sensor renewability
Current catalytic and affinity-based biosensors are designed
such that analysis of a particular molecule will eventually
exhaust a finite supply of enzyme or molecular binding
partner. Of course, in vitro, this presents little problem,
because one can refresh the sensor by replacing, in the case
of an immunosensor, the supply of antibodies [81]. In vivo,
however, the story is something different as the device is
supposed to embrace the concept of laissez-faire; e.g., the
device needs to be self-sustaining for a significant amount
of time. Concomitant with the exhaustion of antibodies is
the production of waste, something, again, inconsequential
in vitro, but unacceptable in vivo where toxicity quickly
becomes an issue [82].
Again taking example of affinity-based sensors, if the
uptake and release of antigen from the sensing surface can
be controlled by external factors, the antigen–antibody
interaction will, in essence, be reusable allowing this type
of implantable sensors to find much wider application and
acceptance. This concept of a reusable sensor has become
known as a ‘‘cleanable’’ sensing surface. Application of
switchable or smart surfaces might be applied to allow for
such a cleanup.
Smart surfaces are those which are able to respond to
environmental stimuli, thereby forming a type of switch
given certain conditions [122]. Various switchable surfaces
initiated by external factors, including photon [123, 124],
charge [125–127], pH [128, 129] and temperature [130]
have been extensively studied. Electrical potential stimu-
lation is a widely used method for controlling surface
properties. It has been employed by using low density self-
assembly monolayer for the design of switchable
hydrophobic/hydrophilic surfaces by reversible conforma-
tional transitions [131, 132]. Electrical potential stimula-
tion could be applied to such an immunosensor allowing
the stimulus to ‘‘clean’’ the sensor.
Sensitivity and selectivity
Briefly mentioned above, more must be said of the balance
between sensitivity and selectivity. Sensitivity is the
magnitude of a biosensor’s response to a particular analyte.
Selectivity refers to its ability to respond only to a specific
analyte among the plethora found in biofluids [129]. Sen-
sitivity and selectivity depend on the materials used to
build the sensor and on the design of the sensor itself and
often represent competing interests as one often improves
at the expense of the other.
Both represent significant challenges in the development
and acceptance of biosensors. To be useful in early disease
states, where biomarkers levels are often less than tens of
picomoles, sensors must be highly sensitive and specific
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[81]. Though there is not yet a sensor developed for BNP
that is highly sensitive and specific, nanotechnology pre-
sents many promising applications to implantable biosen-
sors. Vaddiraju et al. [81] have provided a review of this
emerging synergy. To showcase the technology, we will
briefly discuss silicon nanowire (SiNW) clusters.
Chua et al. [133] have reported the development of
SiNW cluster arrays. Based on electrical detection of
antibody–analyte interaction, they have demonstrated sen-
sitivity to cardiac troponin-T (cTnT) at 1 fg/mL in buffer
solution and down to 30 fg/mL in undiluted human serum
with a 3:1 signal-to-noise ratio. Given high levels of total
protein concentration, this concept has also demonstrated
high specificity. Because the sensor is electronics based, it
can be queried every second, allowing real-time detection
of a particular analyte. The sensor boasts a total of 36
clusters of 5 nanowires each, leaving the potential for
monitoring of multiple analytes [133].
Perhaps the greatest drawback to the application of this
nanotechnology to implantable biosensors is, ironically, its
size. The sensor developed by Chua et al. [133] measures
40 mm 9 25 mm at the base, hardly capable of in vivo
implantation. Perhaps if the sensor were to be designed for
single-analyte specificity (as opposed to[35 analytes), the
sensor could be sufficiently miniaturized for in vivo
application. Indeed, the larger, pluri-specific sensor could
be used as a screening device where a smaller, unispecific
device could be used to continuously monitor an analyte of
interest. Another barrier to the widespread use of nan-
otechnology is its monetary cost. As the technology
develops this cost will decrease, but in status quo, eco-
nomic barriers inhibit nanotechnology’s development by
researchers who cannot afford the machinery to develop
the sensor and its pilot use by physicians who cannot afford
to venture from the beaten and less expensive path of
bedside assays and benchtop biosensors. Notwithstanding
these disadvantages, nanotechnology still holds promising
potential.
Summary and roadmap for future
As BNP continues to increase in its diagnostic importance,
there will be increased interest in its quantification. To be
able to classify a patient’s condition, administer-guided
treatment, and measure the success thereof while predicting
future outcomes, however, is no small task. In this review,
we have attempted to survey the current research and
progress in both the field of BNP research and how BNP is
currently and will 1 day be measured in the human body.
Ideally, the community will develop a device that can
continuously measure BNP in vivo for extended periods of
time.
Compliance with ethical standards
Conflict of interest R. Maalouf and S. Bailey declare that they have
no conflict of interest.
Ethical standard The manuscript does not contain clinical studies
or patient data.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,
Cushman M, de Ferranti S, Despre´s JP, Fullerton HJ, Howard
VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Licht-
man JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB,
McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino
ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey
DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A,
Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB,
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee (2015) Heart disease and stroke statis-
tics—2015 update: a report from the American Heart Associa-
tion. Circulation 131:e29–e322
2. McDonnell B, Hearty S, Leonard P, O’Kennedy R (2009) Car-
diac biomarkers and the case for point-of-care testing. Clin
Biochem 42:549–561
3. Moriates C, Maisel A (2010) The utility of biomarkers in sorting
out the complex patient. Am J Med 123:393–399
4. Bozkurt B, Mann DL (2003) Use of biomarkers in the man-
agement of heart failure: are we there yet? Circulation
107:1231–1233
5. Yang Z, Min Zhou D (2006) Cardiac markers and their point-of-
care testing for diagnosis of acute myocardial infarction. Clin
Biochem 39:771–780
6. Konstam MA (2007) Natriuretic peptides and cardiovascular
events: more than a stretch. JAMA 297:212–214
7. Caldwell MA, Howie JN, Dracup K (2003) BNP as discharge
criteria for heart failure. J Card Fail 9:416–422
8. Lee DS, Vasan RS (2005) Novel markers for heart failure
diagnosis and prognosis. Curr Opin Cardiol 20:201–210
9. Iqbal N, Wentworth B, Choudhary R, De La Parra Landa A,
Kipper B, Fard A, Maisel AS (2012) Cardiac biomarkers: new
tools for heart failure management. Cardiovac Diagn Ther
2:147–164
10. Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K,
Giannopoulos G, Bouras G, Pyrgakis V, Cleman MW (2013)
NTproBNP: an important biomarker in cardiac diseases. Curr
Top Med Chem 13:82–94
11. Motiwala SR, Januzzi JL Jr (2013) The role of natriuretic pep-
tides as biomarkers for guiding the management of chronic heart
failure. Clin Pharmacol Ther 93:57–67
12. Coco G, Jerie P (2015) Assessing the benefits of natriuretic
peptides-guided therapy in chronic heart failure. Cardiol J
22:5–11
13. Balion C, McKelvie R, Don-Wauchope AC, Santaguida PL,
Oremus M, Keshavarz H, Hill SA, Booth RA, Ali U, Brown JA,
Bustamam A, Sohel N, Raina P (2014) B-type natriuretic
574 Heart Fail Rev (2016) 21:567–578
123
peptide-guided therapy: a systematic review. Heart Fail Rev
19:553–564
14. Troughton RW, Frampton CM, Yandle TG, Espiner EA,
Nicholls MG, Richards AM (2000) Treatment of heart failure
guided by plasma aminoterminal brain natriuretic peptide (N-
BNP) concentrations. Lancet 355:1126–1130
15. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H
(2005) BNP-guided therapy not better than expert’s clinical
assessment for beta-blocker titration in patients with heart fail-
ure. Congest Heart Fail 11:248–253
16. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal
E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal
A, Juille`re Y (2007) Plasma brain natriuretic peptide-guided
therapy to improve outcome in heart failure: the STARS-BNP
Multicenter Study. J Am Coll Cardiol 49:1733–1739
17. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Ricken-
bacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI,
Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R,
Brunner-La Rocca HP, Investigators TIME-CHF (2009) BNP-
guided vs symptom-guided heart failure therapy: the Trial of
Intensified vs Standard Medical Therapy in Elderly Patients
With Congestive Heart Failure (TIMECHF) randomized trial.
JAMA 301:383–392
18. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM,
Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM
(2009) N-terminal pro-B-type natriuretic peptide-guided treat-
ment for chronic heart failure: results from the BATTLE-
SCARRED (NT-proBNPAssisted Treatment To Lessen Serial
Cardiac Readmissions and Death) trial. J Am Coll Cardiol
55:53–60
19. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K,
Dahlstro¨m U (2010) Improved pharmacological therapy of
chronic heart failure in primary care: a randomized Study of NT-
proBNP Guided Management of Heart Failure—SIGNAL-HF
(Swedish Intervention study—guidelines and NT-proBNP
AnaLysis in Heart Failure). Eur J Heart Fail 12:1300–1308
20. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van
der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge
N, Meeder JG, Prins M, Pinto YM (2010) Management of
chronic heart failure guided by individual N-terminal pro-B-type
natriuretic peptide targets: results of the PRIMA (Can PRo-
brain-natriuretic peptide guided therapy of chronic heart failure
IMprove heart fAilure morbidity and mortality?) study. J Am
Coll Cardiol 56:2090–2100
21. Anguita M, Esteban F, Castillo JC, Mazuelos F, Lo´pez-Grana-
dos A, Arizo´n JM, Sua´rez De Lezo J (2010) Usefulness of brain
natriuretic peptide levels, as compared with usual clinical con-
trol, for the treatment monitoring of patients with heart failure.
Med Clin (Barc) 135:435–440
22. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti
S, Wagner B, Pacher R (2010) N-Terminal pro-B-type natri-
uretic peptide-guided, intensive patient management in addition
to multidisciplinary care in chronic heart failure a 3-arm,
prospective, randomized pilot study. J Am Coll Cardiol
55:645–653
23. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Man-
cini DM, Fiuzat M, Stevenson LW, O’Connor CM (2011) The
STARBRITE trial: a randomized, pilot study of B-type natri-
uretic peptide-guided therapy in patients with advanced heart
failure. J Card Fail 17:613–621
24. Karlstro¨m P, Alehagen U, Boman K, Dahlstro¨m U, UPSTEP-
Study Group (2011) Brain natriuretic peptide-guided treatment
does not improve morbidity and mortality in extensively
treated patients with chronic heart failure: responders to
treatment have a significantly better outcome. Eur J Heart Fail
13:1096–1103
25. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A,
Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-
Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD,
Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthama-
lingam S, Semigran MJ (2011) Use of amino-terminal pro-B-
type natriuretic peptide to guide outpatient therapy of patients
with chronic left ventricular systolic dysfunction. J Am Coll
Cardiol 58:1881–1889
26. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gam-
bardella F, Rengo G, Leosco D, Perrone-Filardi P (2013)
Natriuretic peptide-guided therapy in chronic heart failure: a
meta-analysis of 2,686 patients in 12 randomized trials. PLoS
ONE 8:e58287
27. Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new
natriuretic peptide in porcine brain. Nature 332:78–81
28. Sudoh T, Minamino N, Kangawa K, Matsuo H (1988) Brain
natriuretic peptide-32: N-terminal six amino acid extended form
of brain natriuretic peptide identified in porcine brain. Biochem
Biophys Res Commun 155:726–732
29. Matsuura H, Sato Y, Niwa O, Mizutani F (2005) Electrochem-
ical enzyme immunoassay of a peptide hormone at picomolar
levels. Anal Chem 77:4235–4240
30. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y,
Shirakami G, Jougasaki M, Obata K, Yasue H (1991) Brain
natriuretic peptide as a novel cardiac hormone in humans.
Evidence for an exquisite dual natriuretic peptide system, atrial
natriuretic peptide and brain natriuretic peptide. J Clin Invest
87:1402–1412
31. Nakamura S, Naruse M, Naruse K, Kawana M, Nishikawa T,
Hosoda S, Tanaka I, Yoshimi T, Yoshihara I, Inagami T (1991)
Atrial natriuretic peptide and brain natriuretic peptide coexist in
the secretory granules of human cardiac myocytes. Am J
Hypertens 4:909–912
32. Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac
endocrine function is an essential component of the homeostatic
regulation network: physiological and clinical implications. Am
J Physiol Heart Circ Physiol 290:H17–H29
33. De Lemos JA, McGuire DK, Drazner MH (2003) B-type
natriuretic peptide in cardiovascular disease. Lancet
362:316–322
34. Rodeheffer RJ (2004) Measuring plasma B-type natriuretic
peptide in heart failure: good to go in 2004? J Am Coll Cardiol
44:740–749
35. Wilkins MR, Redondo J, Brown LA (1997) The natriuretic-
peptide family. Lancet 349:1307–1310
36. Vanderheyden M, Bartunek J, Goethals M (2004) Brain and
other natriuretic peptides: molecular aspects. Eur J Heart Fail
6:261–268
37. Yamanouchi S, Kudo D, Endo T, Kitano Y, Shinozawa Y (2010)
Blood N-terminal proBNP as a potential indicator of cardiac
preload in patients with high volume load. Tohoku J Exp Med
221:175–180
38. King L, Wilkins MR (2002) Natriuretic peptide receptors and
the heart. Heart 87:314–315
39. Kuhn M (2004) Molecular physiology of natriuretic peptide
signaling. Basic Res Cardiol 99:76–82
40. Witthaut R (2004) Science review: natriuretic peptides in critical
illness. Crit Care 8:342–349
41. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger
JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett
JC Jr (2004) Brain natriuretic peptide enhances renal actions of
furosemide and suppresses furosemide-induced aldosterone
activation in experimental heart failure. Circulation 109:
1680–1685
42. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M,
Scharpe S, De Meester I (2006) Dipeptidyl-peptidase IV
Heart Fail Rev (2016) 21:567–578 575
123
converts intact B-type natriuretic peptide into its des-SerPro
Form. Clin Chem 52:82–87
43. Kroll MH, Srisawasdi P (2007) The clearance of BNP modeled
using the NT-proBNP-BNP relationship. Biosystems
88:147–155
44. Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui KI
(1999) Enzymatic inactivation of major circulating forms of
atrial and brain natriuretic peptides. Eur J Pharmacol
370:307–312
45. Walther T, Stepan H, Pankow K, Gembardt F, Faber R,
Schultheiss HP, Siems WE (2004) Relation of ANP and BNP
to their N-terminal fragments in fetal circulation: evidence
for enhanced neutral endopeptidase activity and resistance of
BNP to neutral endopeptidase in the fetus. BJOG
111:452–455
46. Kenny AJ, Bourne A, Ingram J (1993) Hydrolysis of human and
pig brain natriuretic peptides, urodilatin, C-type natriuretic
peptide and some C-receptor ligands by endopeptidase-24.11.
Biochem J 291:83–88
47. McCullough PA, Omland T, Maisel AS (2003) B-type natri-
uretic peptides: a diagnostic breakthrough for clinicians. Rev
Cardiovasc Med 4:72–80
48. Norman JA, Little D, Bolgar M, Di Donato G (1991) Degra-
dation of brain natriuretic peptide by neutral endopeptidase:
species specific sites of proteolysis determined by mass spec-
trometry. Biochem Biophys Res Commun 175:22–30
49. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki
M, Sugita K, Yamada K (2002) Molecular forms of human brain
natriuretic peptide in plasma. Clin Chim Acta 316:129–135
50. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H
(2001) Degradation of human brain natriuretic peptide (BNP) by
contact activation of blood coagulation system. Clin Chim Acta
305:181–186
51. Vittorini S, Prontera C, Zucchelli GC, Clerico A (2007) Cardiac
natriuretic hormones: methodological aspects. Immuno-Anal
Biol Spec 22:236–246
52. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB,
Bluestein BI (2004) The effect of class-specific protease inhi-
bitors on the stabilization of B-type natriuretic peptide in human
plasma. Clin Chim Acta 340:163–172
53. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G,
Richard M (1999) The amino terminal regions of proBNP and
proANP oligomerise through leucine zipper-like coiled-coil
motifs. Biochem Biophys Res Commun 255:495–501
54. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T (2003)
Characterization of molecular forms of probrain natriuretic
peptide in human plasma. Clin Chim Acta 334:233–239
55. Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA,
Stephen Pollitt N (2006) The precursor to B-type natriuretic
peptide is an O-linked glycoprotein. Arch Biochem Biophys
451:160–166
56. Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M,
Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA
(2007) Evidence for functional heterogeneity of circulating
B-type natriuretic peptide. J Am Coll Cardiol 49:1071–1078
57. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS,
Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple
FS, Esakova TV, Filatov VL, Katrukha AG (2007) The brain
natriuretic peptide (BNP) precursor is the major immunoreactive
form of BNP in patients with heart failure. Clin Chem
53:866–873
58. Davlouros PA, Karatza AA, Xanthopoulou I, Dimitriou G,
Georgiopoulou A, Mantagos S, Alexopoulos D (2011) Diag-
nostic role of plasma BNP levels in neonates with signs of
congenital heart disease. Int J Cardiol 147:42–46
59. Blonde´-Cynober F, Morineau G, Estrugo B, Fillie E, Aussel C,
Vincent JP (2011) Diagnostic and prognostic value of brain
natriuretic peptide (BNP) concentrations in very elderly heart
disease patients: specific geriatric cut-off and impacts of age,
gender, renal dysfunction, and nutritional status. Arch Gerontol
Geriatr 52:106–110
60. Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V,
Maisel A (2005) Evaluation of B-type natriuretic peptide (BNP)
levels in normal and preeclamptic women. Am J Obstet Gynecol
193:450–454
61. Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek
J, Bozkurt B (2009) Reduction in BNP levels with treatment of
decompensated heart failure and future clinical events. J Card
Fail 15:293–299
62. Mair J, Falkensammer G, Poelzl G, Hammerer-Lercher A,
Griesmacher A, Pachinger O (2007) B-type natriuretic peptide
(BNP) is more sensitive to rapid hemodynamic changes in acute
heart failure than N-terminal proBNP. Clin Chim Acta
379:163–166
63. Scott PA, Barry J, Roberts PR, Morgan JM (2009) Brain natri-
uretic peptide for the prediction of sudden cardiac death and
ventricular arrhythmias: a meta-analysis. Eur J Heart Fail
11:958–966
64. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore
SA, Januzzi JL Jr (2010) Design and methods of the Pro-B Type
natriuretic peptide Outpatient Tailored Chronic Heart Failure
Therapy (PROTECT) study. Am Heart J 159:532–538
65. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T,
Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S (1993)
Ventricular expression of brain natriuretic peptide in hyper-
trophic cardiomyopathy. Circulation 88:372–380
66. Del Ry S, Clerico A, Giannessi D, Andreassi MG, Caprioli R,
Iascone MR, Ferrazzi P, Biagini A (2000) Measurement of brain
natriuretic peptide in plasma samples and cardiac tissue extracts
by means of an immunoradiometric assay method. Scand J Clin
Lab Invest 60:81–90
67. Kono M, Yamauchi A, Tsuji T (1993) An immunoradiometric
assay for brain natriuretic peptide in human plasma. Jpn Soc
Nucl Med Technol 13:2–7
68. Yandle T, Richards A, Gilbert A, Fisher S, Holmes S, Espiner E
(1993) Assay of brain natriuretic peptide (BNP) in human
plasma: evidence for high molecular weight BNP as a major
plasma component in heart failure. J Clin Endocrinol Metab
76:832–838
69. Wolf M, Juncker D, Michel B, Hunziker P, Delamarche E
(2004) Simultaneous detection of C-reactive protein and other
cardiac markers in human plasma using micromosaic
immunoassays and self-regulating microfluidic networks. Bio-
sens Bioelectron 19:1193–1202
70. IFCC. Analytical characteristics of commercial MR-proANP,
BNP and NT-proBNP assays as per the manufacturer. http://
www.ifcc.org/media/276711/IFCC%20NP%20Assay%20Table
%20November%202014.pdf
71. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J,
Pagani F, Christenson RH, Jaffe AS, Committee on Standard-
ization of Markers of Cardiac Damage of the IFCC (2005)
Quality specifications for B-type natriuretic peptide assays. Clin
Chem 51:486–493
72. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg
SM, Redfield MM, Burnett JC Jr (2007) Immunoreactivity and
guanosine 30,50-cyclic monophosphate activating actions of
various molecular forms of human B-type natriuretic peptide.
Hypertension 49:1114–1119
73. Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R,
Franzini M, Zucchelli GC, Plebani M, on behalf of SIBIOC
576 Heart Fail Rev (2016) 21:567–578
123
(2012) State of the art of BNP and NT-proBNP immunoassays:
the cardioormocheck study. Clin Chim Acta 414:112–119
74. Cauliez B, Santos H, Bauer F, Basuyau JP, Nadolny A, Galpy G
(2012) Cross-reactivity with endogenous proBNP from heart
failure patients for three commercial BNP immunoassays. Clin
Chim Acta 413:337–338
75. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le
A, Perichon R, Jaffe AS (2011) Comparison of mass spec-
trometry and clinical assay measurements of circulating frag-
ments of B-type natriuretic peptide in patients with chronic heart
failure. Cir Heart Fail 4:355–360
76. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM (2010) Inter-
pretation and use of natriuretic peptides in non-congestive heart
failure settings. Yonsei Med J 51:151–163
77. Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Bur-
nett JC, Muddiman DC (2005) Quantitative mass spectral evi-
dence for the absence of circulating brain natriuretic peptide
(BNP-32) in severe human heart failure. PNAS
102:17442–17447
78. Wang J, Hong B, Kai J, Han J, Zou Z, Ahn CH, Kang KA (2009)
Mini sensing chip for point-of-care acute myocardial infarction
diagnosis utilizing micro-electro-mechanical system and nano-
technology. Adv Exp Med Biol 645:101–107
79. Reach G, Wilson GS (1992) Can continuous glucose monitoring
be used for the treatment of diabetes? Anal Chem 64:381A–386A
80. Leung A, Shankar PM, Mutharasan R (2007) A review of fiber-
optic biosensors. Sens Actuators B Chem 125:688–703
81. Vaddiraju S, Tomazos I, Burgess DJ, Jain FC, Papadimi-
trakopoulos F (2010) Emerging synergy between nanotechnol-
ogy and implantable biosensors: a review. Biosens Bioelectron
25:1553–1565
82. Manda V, Bennett TD, Yang Z (2005) Implantable biosensor
devices for monitoring cardiac marker molecules. International
application No.: PCT/US2004/027958
83. Matsuura H, Sato Y, Niwa O, Mizutani F (2005) Surface elec-
trochemical enzyme immunoassay for the highly sensitive
measurement of B-type natriureric peptide. Sens Actuators B
Chem 108:603–607
84. Mizutani F, Matsuura H (2005) Surface electrochemistry for the
construction of highly sensitive immunoassay system. Curr Appl
Phys 5:98–101
85. Kurita R, Yokota Y, Sato Y, Mizutani F, Niwa O (2006) On-
chip enzyme immunoassay of a cardiac marker using a
microfluidic device combined with a portable surface plasmon
resonance system. Anal Chem 78:5525–5531
86. Teramura Y, Arima Y, Iwata H (2006) Surface plasmon reso-
nance-based highly sensitive immunosensing for brain natri-
uretic peptide using nanobeads for signal amplification. Anal
Biochem 357:208–215
87. Mischak RP, Lim GA, Scardina JM (2000) Human brain natri-
uretic peptides. United States Patent. Patent No.: 6,124,430 A
88. Prasad S, Selvam AP, Reddy RK, Love A (2013) Silicon
nanosensor for diagnosis of cardiovascular proteomic markers.
J Lab Autom 18:143–151
89. Lee I, Luo X, Huang J, Cui XT, Yun M (2012) Detection of
cardiac biomarkers using single polyaniline nanowire-based
conductometric biosensors. Biosensors 2:205–220
90. Hong B, Kai J, Ren Y, Han J, Zou Z, Ahn CH, Kang KA (2008)
Highly sensitive rapid, reliable, and automatic cardiovascular
disease diagnosis with nanoparticle fluorescence enhancer and
mems. Adv Exp Med Biol 614:265–273
91. Hirsch IB, Armstrong D, Bergenstal RM, Buckingham B, Childs
BP, Clarke WL, Peters A, Wolpert H (2008) Clinical application
of emerging sensor technologies in diabetes management: con-
sensus guidelines for continuous glucose monitoring (CGM).
Diabetes Technol Ther 10:232–244
92. Vincze G, Barner JC, Lopez D (2004) Factors associated with
adherence to self-monitoring of blood glucose among persons
with diabetes. Diabetes Educ 30:112–125
93. Wu AHB (2006) Serial testing of B-type natriuretic peptide and
NTpro-BNP for monitoring therapy of heart failure: the role of
biologic variation in the interpretation of results. Am Heart J
152:828–834
94. Goodall TA, Halford WK (1991) Self-management of diabetes
mellitus: a critical review. Health Psychol 10:1–8
95. Hitchcock RW, Sorenson JL (2005) Implantable biosensor
system, apparatus and method. United States Patent. Patent No.:
US 6,965,791 B1
96. Pickup JC, Hussain F, Evans ND, Sachedina N (2005) In vivo
glucose monitoring: the clinical reality and the promise. Biosens
Bioelectron 20:1897–1902
97. Wilson GS, Gifford R (2005) Biosensors for real-time in vivo
measurements. Biosens Bioelectron 20:2388–2403
98. Heller A, Pishko MV (2001) Subcutaneous glucose electrode.
United States Patent. Patent No.: US 6.329,161 B1
99. Guiseppi-Elie A, Brahim S, Slaughter G, Ward KR (2005)
Design of a subcutaneous implantable biochip for monitoring of
glucose and lactate. IEEE Sens J 5:345–355
100. Mastrototaro J (1999) The MiniMed continuous glucose moni-
toring system (CGMS). J Pediatr Endocrinol Metab 3:751–758
101. Bailey T, Zisser H, Chang A (2009) New features and perfor-
mance of a next-generation seven-day continuous glucose
monitoring system with short lag time. Diabetes Technol Ther
11:749–755
102. Chia CW, Saudek CD (2004) Glucose sensors: toward closed
loop insulin delivery. Endocrinol Metab Clin North Am
33:175–195
103. Brister M, Saint S, Neale PV, Kline DS, Thrower JP, Masterson
S, Codd DS (2010) Transcutaneous analyte sensor. United States
Patent. Patent No.: US 7,654,956 B2
104. Potkay J (2008) Long term, implantable blood pressure moni-
toring systems. Biomed Microdevices 10:379–392
105. Chamberlain JJ, Small D (2008) Case study: successful use of a
single subcutaneous continuous glucose monitor sensor for
28 days in a patient with type 1 diabetes. Clin Diabetes
26:138–139
106. Garg SK, Voelmle MK, Gottlieb P (2009) Feasibility of 10-day
use of a continuous glucose-monitoring system in adults with
type 1 diabetes. Diabetes Care 32:436–438
107. Mortellaro M, DeHennis A (2014) Performance characterization
of an abiotic and fluorescent-based continuous glucose moni-
toring system in patients with type 1 diabetes. Biosens Bio-
electron 61:227–231
108. Hoss U, Budiman ES, Liu H, Christiansen MP (2013) Contin-
uous glucose monitoring in the subcutaneous tissue over a
14-day sensor wear period. J Diabetes Sci Technol 7:1210–1219
109. GlySens Incorporated (2015) GlySens incorporated secures
FDA approval to extend second generation fully-implanted
CGM sensor evaluation from 6 to 12 months. http://glysens.
com/press-releases/glysens-incorporated-secures-fda-approval-
to-extend-second-generation-fully-implanted-cgm-sensor-evalu
ation-from-6-to-12-months/. Accessed Nov 2015
110. Bowdle T (2002) Complications of invasive monitoring. Anes-
thesiol Clin N Am 20:571–588
111. The Juvenile Diabetes Research Foundation Continuous Glu-
cose Monitoring Study Group (2008) Continuous glucose
monitoring and intensive treatment of type 1 diabetes. N Engl J
Med 359:1464–1476
112. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt
NM (2012) Short- and long-term effects of real-time continuous
glucose monitoring in patients with type 2 diabetes. Diabetes
Care 35:32–38
Heart Fail Rev (2016) 21:567–578 577
123
113. Chow EY, Beier BL, Francino A, Chappell WJ, Irazoqui PP
(2009) Toward an implantable wireless cardiac monitoring
platform integrated with an FDA-approved cardiovascular stent.
J Intervent Cardiol 22:479–487
114. Shelchuk A (2007) Implantable biosensor and methods for
monitoring cardiac health. United States Patent. US Patent
7,223,237 B2
115. Villaseca EH, Dublin GL, Goedeke SD, Haubrich GJ (2001)
Telemetry system for implantable medical devices. United
States Patent US Patent 6,169,925 B1
116. Gifford R, Kehoe JJ, Barnes SL, Kornilayev BA, Alterman MA,
Wilson GS (2006) Protein interactions with subcutaneously
implanted biosensors. Biomaterials 27:2587–2598
117. Wisniewski N, Reichert M (2000) Methods for reducing
biosensor membrane biofouling. Colloids Surf B Biointerfaces
18:197–219
118. Gant RM, Abraham AA, Hou Y, Cummins BM, Grunlan MA,
Cote´ GL (2010) Design of a self-cleaning thermoresponsive
nanocomposite hydrogel membrane for implantable biosensors.
Acta Biomater 6:2903–2910
119. Adiga SP, Jin C, Larry A, Curtiss LA, Monteiro-Riviere NA,
Narayan RJ (2009) Nanoporous membranes for medical and
biological applications. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 1:568–581
120. Abraham AA, Fei R, Cote´ GL, Grunlan MA (2013) Self-
cleaning membrane to extend the lifetime of an implanted glu-
cose biosensor. ACS Appl Mater Interfaces 5:12832–12838
121. Brault ND, Gao C, Xue H, Piliarik M, Homola J, Jiang S, Yu Q
(2010) Ultra-low fouling and functionalizable zwitterionic
coatings grafted onto SiO2 via a biomimetic adhesive group for
sensing and detection in complex media. Biosens Bioelectron
25:2276–2282
122. Ligler FS, Gaber BP, Kusterbeck AW, Wemhoff GA (2001)
Flow immunosensor apparatus. United States Patent. Patent No.:
US 6,245,296 B1
123. Cooper CGF, MacDonald JC, Soto E, McGimpsey WG (2004)
Non-covalent assembly of a photoswitchable surface. J Am
Chem Soc 126:1032–1033
124. Russell TP (2002) Surface-responsive materials. Science
297:964–967
125. Delorme N, Bardeau JF, Bulou A, Poncin-Epaillard F (2005)
Azobenzene-containing monolayer with photoswitchable wet-
tability. Langmuir 21:12278–12282
126. Lahann J, Mitragotri S, Tran TN, Kaido H, Sundaram J, Choi IS,
Hoffer S, Somorjai GA, Langer R (2003) A reversibly switching
surface. Science 299:371–374
127. Weissmuller J, Viswanath RN, Kramer D, Zimmer P, Wur-
schum R, Gleiter H (2003) Charge-induced reversible strain in a
metal. Science 300:312–315
128. Hiramatsu H, Osterloh FE (2003) pH-controlled assembly and
disassembly of electrostatically linked CdSe–SiO2 and Au–SiO2
nanoparticle clusters. Langmuir 19:7003–7011
129. Liu Y, Mu L, Liu B, Kong J (2005) Controlled switchable
surface. Chem Eur J 11:2622–2631
130. Matthews JR, Tuncel DNS, Jacobs RMJ, Bain CD, Anderson
HL (2003) Surfaces designed for charge reversal. J Am Chem
Soc 125:6428–6433
131. Albrecht T, Armbruster S, Keller S, Strobl G (2001) Kinetics of
reversible surface crystallization and melting in poly(ethylene
oxide): effect of crystal thickness observed in the dynamic heat
capacity. Eur Phys J E 6:237–243
132. Liu Y, Mu L, Liu B, Zhang S, Yang P, Kong J (2004) Controlled
protein assembly on a switchable surface. Chem Commun
10:1194–1195
133. Chua JH, Chee RE, Agarwal A, Wong SM, Zhang GJ (2009)
Label-free electrical detection of cardiac biomarker with com-
plementary metal-oxide semiconductor-compatible silicon
nanowire sensor arrays. Anal Chem 81:6266–6627
578 Heart Fail Rev (2016) 21:567–578
123
